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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death globally and in Canada. Diabetes and hypertension
are major risk factors for CVD events. Despite the increasing availability of effective treatments, the majority of diabetic and
hypertensive patients do not have adequate blood pressure and glycemic control. One of the major contributors is poor treatment
adherence.
Objective: This study aims to evaluate the impact of treatment adherence for patients with both diabetes and hypertension on
acute severe CVD events and intermediate clinical outcomes in Canadian primary care settings.
Methods: We will conduct a population-based retrospective cohort study of patients living with both diabetes and hypertension
in Ontario, Canada, between January 1, 2008, and March 31, 2018. The Social Cognitive Theory will be used as a conceptual
framework by which to frame the reciprocal relationship between treatment adherence, personal factors, and environmental
determinants and how this interplay impacts CVD events and clinical outcomes. Data will be derived from the Diabetes Action
Canada National Data Repository. A time-varying Cox proportional hazards model will be used to estimate the impacts of treatment
adherence on CVD morbidity and mortality. Multivariable linear regression models and hierarchical regression models will be
used to estimate the associations between treatment adherence of different medication categories and intermediate clinical
outcomes. Our primary outcome is the association between treatment adherence and the risk of acute severe CVD events, including
CVD mortality. The secondary outcome is the association between treatment adherence and intermediate clinical outcomes
including diastolic and systolic blood pressures, glycated hemoglobin, low-density lipoprotein cholesterol, and total cholesterol.
Owing to data limitation, we use medication prescriptions as a proxy to estimate treatment adherence. We assume that a patient
adhered to medications if she or he had any prescription record in the 4 preceding quarters and 1 quarter after each quarter of
interest. Acute severe CVD events are defined based on the World Health Organization’s Monitoring Trends and Determinants
in Cardiovascular Disease Project, including acute coronary heart disease, stroke, and heart failure. As causes of death are not
available, the number of CVD deaths will be computed using the most recent systolic blood pressure distributions and the
population attributable risks related to systolic blood pressure level.
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Results: The project was funded by Diabetes Action Canada (reference number: 503854) and approved by the University of
Toronto Research Ethics Board (reference number: 36065). The project started in June 2018 and is expected to be finished by
September 2019.
Conclusions: The findings will be helpful in identifying the challenges of treatment adherence for diabetic and hypertensive
patients in primary care settings. This will also help to develop intervention strategies to promote treatment adherence for patients
with multi-morbidities.
International Registered Report Identifier (IRRID): DERR1-10.2196/13571
(JMIR Res Protoc 2019;8(5):e13571)   doi:10.2196/13571
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Introduction
Background
Cardiovascular disease (CVD) is the leading cause of death in
Canada, accounting for one-third of deaths nationally [1].
Diabetes and hypertension are major risk factors for CVDs [2-4].
In 2017, approximately 7.3% and 17.8% of Canadians aged 12
years and older reported being diagnosed with diabetes and
hypertension, respectively [5]. Diabetes and hypertension are
the 2 most common comorbid chronic diseases seen in primary
care consultations. Hypertension is reported in over two-thirds
of patients with type 2 diabetes [6], whereas nearly 50% of
patients with hypertension are diabetic [7]. Despite the
increasing availability of effective treatment regiments and
guidelines, approximately half of the treated patients do not
have adequate blood pressure and glycemic control [8,9]. One
of the major contributors to inadequate control is poor treatment
adherence [9,10]. Treatment adherence is defined as the degree
to which the patient’s behavior corresponds with the agreed
recommendations from a health care provider [11]. Adherence
to antihypertension and antidiabetes medications is proven to
reduce CVD morbidity and mortality, hospitalizations, and
health expenditure [11-17]. Given the potential impacts of
treatment adherence on CVD morbidity and mortality,
quantifying treatment adherence and its impacts will help in the
development of intervention strategies to improve treatment
adherence for patients in primary care settings. This includes
the use of patient-centered approaches such as concordance,
where doctors elicit patients’ views, inform patients of the pros
and cons of taking medicine, and involve patients in treatment
decision making [18]. This type of informed and shared decision
making is believed to improve patient satisfaction, adherence,
and treatment outcomes [19]. Unfortunately, the process of
patient-doctor communication is often not recorded and cannot
be quantified using traditional medical records to understand
adherence behaviors.
Treatment adherence can be measured using either subjective
or objective methods. One of the most frequently used subjective
measures is the Morisky Medication Adherence Scale [20],
which is a patient self-reported tool with 8 items related to
medication-taking behaviors that can be transformed into an
adherence score [21,22]. Morisky scale heavily relies on
patient’s attitudes toward their medications rather than actual
medication-taking behaviors and is vulnerable to significant
recall bias [21,22]. Patients tend to underreport their
nonadherence to avoid disapproval from their physicians or
researchers administering the test [17]. A major limitation of
conducting objective measures of adherence is that
administrative databases often do not record medication taking.
Proxy measures such as prescription refills are used [17] with
the assumption that prescription refill patterns correspond to
medication-taking behavior [23-25]. However, medication refill
patterns can vary substantially across different health care
providers and settings.
Up to now, there were limited studies investigating medication
treatment adherence and its association with CVD events [26-35]
and clinical outcomes [35-40] (Multimedia Appendix 1). Using
refill adherence, previous studies have reported that lower
adherence (<80%) levels were associated with higher risk of
CVD [26], all-cause mortality, and hospitalization for CVD
after adjusting for demographic, socioeconomic status (SES),
and baseline clinical characteristics [29]; higher adherence to
statins (>80%) was associated with significant reduction in
low-density lipoprotein cholesterol (LDL-C) in patients with
diabetes [36]. In these studies, refill adherence was measured
by the medication possession ratio (MPR), reporting the
proportion of days with medications on hand during the
follow-up. In Canada, there have been 12 studies that were
investigated for treatment adherence of patients with diabetes
[41-44], hypertension [30-32,34,45,46], or both [47]
(Multimedia Appendix 1). Of these studies, 5 reported a negative
association between treatment adherence and chronic heart
failure [30,31], end-stage renal disease [31], mortality [32], a
composite of all-cause death and hospitalization for acute
myocardial infarction, heart failure, or stroke [33], and combined
CVD events (coronary artery disease, cerebrovascular disease,
and chronic heart failure) and hospitalization costs [34]. Using
refill adherence, previous studies have showed that lower
treatment adherence (<80%) was associated with higher risk of
coronary disease [36], cerebrovascular disease [36], and chronic
heart failure [36], after adjustment for demographic and SES
[30]. These studies had several common limitations. First, few
studies examined treatment adherence among patients with
multimorbidities, such as both diabetes and hypertension, which
accounted for the majority of these patients and is in line with
studies showing that multimorbidity and medical complexity
increase with age [48]. Second, most studies examined only one
type of medication adherence, not considering the combined
benefits of adhering to multiple medications in preventing CVD
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events and mortality [49,50]. Third, many studies were
cross-sectional in design and relied on survey- or hospital-based
electronic medical records (EMRs) or had a relatively shorter
follow-up time (<10 years), which limited the studies’ ability
to inform clinical practice at the primary care level.
Theoretical Framework
Treatment adherence is largely viewed, and measured, as a
behavior at the individual level [51]. However, adherence is
multifactorial and influenced by a host of environmental
determinants [52-54]. Although often neglected in adherence
studies, environmental determinants have been reported as
barriers to adherence at the individual level [55]. Thus, we intend
to use Social Cognitive Theory as a lens through which to
conceptualize both personal-related factors and environmental
determinants that may influence treatment adherence. Social
Cognitive Theory explains a reciprocal relationship between
that behavior, personal factors, and environmental determinants,
and in the case of health, this interplay impacts health outcomes
(Figure 1) [56,57].
Other studies of adherence at the individual level have employed
the Health Belief Model or Theory of Planned Behavior to
understand how individuals may engage in adherence behavior;
however, these frameworks are limited in application at the
population level and do not adequately explicate environmental
determinants of adherence behaviors [58-60]. Similarly,
theoretical frameworks that include environmental determinants
at the population level, such as the Social-Ecological Model,
while useful in revealing the environmental, organizational, and
social factors influencing health, are limited in ability to
highlight the behavioral mechanisms underpinning adherence
[61]. Thus, the Social Cognitive Theory, which explicitly
includes environmental determinants and personal factors as
contributing to behavior, is well placed to investigate the
population factors that impact adherence.
Our study seeks to examine the ways in which medication
prescription, as proxy for adherence, impacts on CVD events
and clinical outcomes. As shown in our conceptual framework
(Figure 1), the behavior of treatment adherence operates not
only at the individual level but also cumulatively at the
population level. Similarly, health system touchpoints exist and
exert impact at the population level as part of the environmental
determinants of treatment adherence. These factors also interact
with and are influenced by personal factors; however, in our
analysis, we are controlling for these personal-level elements
to highlight the role of medication prescription as an
environmental determinant. We hypothesize that these
environmental factors, measured by primary care provider
characteristics, medication prescription, and medication regimen
complexity over time, in turn, would impact on individual CVD
events and clinical outcomes. Ultimately, this lens allows us to
consider how population-level considerations, such as health
system touchpoints, impact adherence at the population level.
The results will provide evidence that may inform health policy
and specific health service interventions.
Objectives and Hypotheses
Objective 1: The first objective was to assess the impacts of
treatment adherence on acute severe CVD events in Ontario
between January 1, 2008, and March 31, 2018 (10 years).
Hypothesis 1: Patients with a lower adherence rate
of one or more medications (antihypertension,
antidiabetes, statins, and aspirin) are more likely to
develop acute severe CVD events (including death
from CVD), adjusting for potential confounding
factors.
Objective 2: The second objective was to assess the impacts of
treatment adherence on intermediate clinical outcomes in Ontario
between January 1, 2008, and March 31, 2018.
Hypothesis 2: Patients with a higher adherence rate
are associated with significant improvements in
clinical outcomes including diastolic blood pressure,
systolic blood pressure, glycated hemoglobin (HbA1c),
LDL-C, and total cholesterol (TC), adjusting for
potential confounding factors.
Figure 1. Theoretical framework. CVD: cardiovascular disease.
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Methods
Study Design and Participants
This is a retrospective cohort study using primary care EMR
data. A cohort of patients who were medically diagnosed with
both diabetes and hypertension between January 1, 2008, and
March 31, 2018, will be included in this study.
Inclusion and Exclusion Criteria for Participants
Time to Enter the Cohort
Cases entered the cohort when a medical diagnosis of both
diabetes and hypertension was present and when a prescription
for any antihypertensives or antidiabetic medication was
provided in the EMR. The exclusion criteria included (1) patients
with a past history of any acute severe CVD event, (2) patients
who developed CVD events during follow-up where no date of
CVD event was present, and (3) patients whose follow-up period
was below 6 quarters as we cannot estimate its treatment
adherence. A total of 15,642 eligible participants are identified
in the finial study population (Figures 2 and 3).
Follow-Up
We will retrospectively follow-up all eligible participants until
March 31, 2018 (by months). Follow-up ends when a participant
dies, has any acute severe CVD event, or by the end of the study
(March 31, 2018). For hypotheses related with clinical outcome,
follow-up ends with the participant’s latest diastolic blood
pressure, systolic blood pressure, HbA1c, LDL-C, and TC
outcomes. The follow-up period will be measured approximately
in months and treated as an independent variable.
Data Source
We will utilize the Diabetes Action Canadian National Diabetes
Repository as the data source. The Repository contains
deidentified data from over 100,000 patients living with diabetes,
currently from 4 Canadian provinces (Ontario, Manitoba,
Quebec, and Alberta). Data are extracted from primary care
EMRs of consenting family physicians and nurse practitioners
by regional Practice Based Research Networks who are members
of the Canadian Primary Care Sentinel Surveillance Network
(CPCSSN) and are managed using previously described
processes developed through CPCSSN [61]. The Repository
provides a Secure Analytic Virtual Environment, which is a
privacy compliant research platform in a high-performance
computing center. Approved researchers access the Secure
Analytic Virtual Environment remotely to analyze datasets
derived from Repository data. All projects are reviewed by the
Repository’s Research Governing Committee, composed of at
least 50% patients, to ensure the project’s values are consistent
with those of patients living with diabetes and of their
caregivers. This project was reviewed and approved by the
Research Governing Committee.
Deidentified patient data from contributing practices in the
Diabetes Repository include the following: (1) patient
demographic characteristics, (2) patient health conditions, (3)
physical and laboratory examinations, (4) medication
prescriptions, (5) risk factors, and (6) comorbidities. A data
dictionary that provides information on data elements is
available at the Diabetes Action Canada website.
Figure 2. Cohort participant selection for the association between treatment adherence and cardiovascular disease (CVD) morbidity and mortality.
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Figure 3. Cohort participant selection for the association between treatment adherence and clinical outcomes. CVD: cardiovascular disease; SBP:systolic
blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin; LDL-C: low-density lipoprotein cholesterol.
Exposure and Study Outcomes
Treatment Adherence Rate
Medication adherence rate is considered the exposure of interest.
Medications will be classified as (1) antidiabetic medications,
including metformin, sulfonylurea, and insulin, inhibitors of
dipeptidyl peptidase 4, meglitinide, sodium-glucose
cotransporter-2 inhibitors, thiazolidinedione, and
alpha-glucosidase enzymes, (2) antihypertensive medications,
including angiotensin converting enzyme inhibitors, thiazide
diuretics, beta-blockers, calcium channel blockers, and
angiotensin II receptor blockers, (3) statins, and (4) aspirin. We
will measure patient adherence to each type of prescription if
prescribed. Theoretically, the adherence rate could be calculated
based on the prescription date and refills. However, we cannot
depend on the refills as this information varies highly among
primary care physicians (eg, some refilled every 3 months,
others provided multiple repeats) [62]. Previous research
indicated that lag-lead approach is feasible to estimate adherence
based on time-dependent associations between different
variables (or the same variable) in longitudinal data analysis
[63]. We will use this approach to account for the variation in
refills. Based on a study using the CPCSSN database, we assume
that patients adhered to medications if they had any prescription
record in the 4 preceding quarters and 1 quarter after each
quarter of interest (lag4, lead1) [64].
Cardiovascular Disease Morbidity and Mortality
The primary outcome is the risk of any acute severe CVD events
including mortality to identify cohort members who developed
acute severe CVD events or who died from acute severe CVD
events during the follow-up. Acute severe CVD events are
defined based on the World Health Organization’s Monitoring
Trends and Determinants in Cardiovascular Disease Project,
including acute coronary heart disease (ICD-9 code 410-412,
414), stroke (ICD-9 code 430-438), and heart failure (ICD-9
code 428) [26,65,66].
We could not access the cause of mortality among patients in
this cohort owing to data limitation. Thus, we estimate the cause
of mortality based on previous research by Bundy et al who
offer a method to estimate the association between systolic blood
pressure and CVD mortality [67]. We will apply this method
to identify cohort members who died from CVD events during
the follow-up. This method assumes that the number of CVD
deaths could be increased if the population developed higher
systolic blood pressure treatment levels. The number of CVD
deaths will be computed using systolic blood pressure
distributions and the population attributable risks (PARs) related
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to systolic blood pressure level. A given PAR represents the
proportion of CVD deaths that could be increased by higher
systolic blood pressure levels. We will divide the most recent
systolic blood pressure level into 8 categories (<130, 130-134,
135-139, 140-144, 145-149, 150-154, 155-159, and ≥160
mmHg). The PARs will be calculated using the formula given
in Figure 4, where pi is the proportion of the systolic blood
pressure category i, HRi is the hazard ratio of CVD deaths in
the systolic blood pressure category i, and k is the total number
of systolic blood pressure categories. To estimate hazard ratios
for CVD mortality comparing each of the 8 systolic blood
pressure categories, Bundy et al conducted a network
meta-analysis of 42 antihypertensive clinical trials [68]. We
will use the hazard ratio of CVD death from the meta-analysis
study conducted by Bundy et al. For patients who died during
the follow-up period, we assume that the patient died from CVD
events if the PAR was higher than 50%.
Clinical Outcomes
The secondary outcomes are the most recent clinical treatment
outcomes, including diastolic blood pressure, systolic blood
pressure, HbA1c, LDL-C, and TC.
Figure 4. Formula for population attributable risks (PARs).
Baseline Covariates and Other Covariates
Based on data availability, we will include the following
personal-related factors: (1) patients’ demographic and
socioeconomic characteristics (ie, sex, age, body mass index,
SES, and rurality), (2) risk factors (ie, smoking history, and
alcohol history), (3) comorbidities and its duration by the end
of the follow-up period (ie, chronic obstructive pulmonary
disease, depression, dementia, and Parkinson), and (4) clinical
outcomes at baseline (ie, diastolic blood pressure, systolic blood
pressure, HbA1c, LDL-C, and TC). Environmental determinants
contributing to treatment adherence include those related to
primary care physicians and health systems: (1) physicians’
demographic characteristics (ie, sex, age, and location type) and
(2) complexity of prescription (ie, the types of medication). All
covariates will be treated as baseline covariates except that we
will measure the incidence of comorbidities and the time to
follow-up.
SES is defined according to the Canadian Material Deprivation
Index [69]. The Canadian Material Deprivation Index, a proxy
for individual-level SES based on the most recent 6-digit
residential postal code, is calculated by the average income,
percentage without high school graduation, and the employment
ratio [70]. SES will be categorized into high, average, and low
SES groups.
Statistical Analysis
The analyses will be described separately for objective 1 and
objective 2. We will include participants with nonmissing
information on treatment adherence. Multiple imputations will
be used to replace missing data for baseline covariates, SES,
and comorbidities. Finally, a practice site will be used as a
random effect in each model. All analyses will be performed in
Stata version 13.0 (Stata Corp LP).
Objective 1
For hypothesis 1, a time-varying Cox proportional hazards
model will be performed to evaluate the hazard ratio between
treatment adherence and the incidence of acute severe CVD and
mortality, adjusting for all potential covariates. In addition, the
interactions of adherence to multiple medications will be
included as a block [71] in the Cox proportional hazards model
to examine the combined benefits of adherence in preventing
CVD events and mortality (model 1). Treatment adherence and
acute severe CVD risk is considered as the exposure of interest
and outcomes, respectively. We will measure follow-up time
(in months) from the date of entry into the cohort until the date
of incident acute severe CVD events, died, or the end of the
follow-up period. Kaplan-Meier survival curves for any acute
severe CVD and mortality by treatment adherence level will be
generated by pooling the survival estimates.
Objective 2
For hypothesis 2, 4 multivariable linear regression models will
be used to test the association between treatment adherence and
the most recent clinical outcomes after adjusting for all potential
covariates (model 2-model 5). An adjusted risk ratio with 95%
CI will be generated. We will build the hierarchical regression
[71] into the linear regression models by including the adherence
to different type of medications as a block to test the aggregated
contribution of adherence to clinical outcomes, including
diastolic blood pressure, systolic blood pressure, HbA1c, LDL-C,
and TC.
Sensitivity Analysis
Previous evidence has also indicated that there is no single
correct lag and lead for estimating time-dependent association
[63]. Lag and lead choices are a significantly important issue
in the generalizability of results [62,72]. Therefore, we will
conduct a sensitivity analysis using lag1 and lead 4 (Multimedia
Appendix 2). Additionally, we will examine the consistency of
the results regarding the following: (1) at different treatment
adherence categories (ie, ≥80%, 60% to 80%, 40% to 60%, and
≤40%) and (2) with and without multiple imputation of missing
data on all covariates.
Ethics Approval
The study was approved by the University of Toronto Research
Ethics Board (reference number: 36065). Data were deidentified
when analyzed.
Results
The project was funded in July 2017 under Diabetes Action
Canada (reference number: 503854). The study was approved
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by the University of Toronto Research Ethics Board (reference
number: 36065). The project was started in June 2018. The
results are expected to be finished by September 2019.
Discussion
Strengths
CVD events represent a heavy disease burden on individuals
and their families, the health system, and society in general.
Improving treatment adherence to antihypertensive and
antidiabetic medication has been well documented as an
effective strategy to prevent CVD events. Compared with
previous research, our study has several strengths. First, we will
contribute new knowledge on the association between treatment
adherence, acute CVD events, and clinical outcomes among
patients with both diabetes and hypertension in the primary care
setting. Second, we will examine the combined benefits of
adhering to multiple medications in preventing CVD events and
mortality and clinical treatment outcomes. Finally, our study
provides further knowledge by addressing the limitations of
previous studies, such as inclusion of important potential
confounders such as comorbidities, their duration, and follow-up.
For example, previous research reported that mental health
conditions (ie, depression, anxiety, and dementia) were
important factors when analyzing treatment adherence and CVD
events but lacked the ability to identify such mental conditions
[73,74]. Many studies have used the Charlson Comorbidity
Index [27-29] to explore the combined effects of comorbidities
(ie, chronic obstructive pulmonary disease, depression, chronic
kidney disease, and dementia), but this approach does not reflect
the role of individual comorbidities. Furthermore, these studies
did not control for duration of comorbidities. Finally, baseline
clinical characteristics such as HbA1c, lipids, blood pressure,
and body mass index are also important confounding factors,
which may have a direct impact on CVD risk and clinical
treatment outcomes [75]. However, few studies control for these
factors. We will address the limitations by controlling body
mass index, diastolic blood pressure, systolic blood pressure,
HbA1c, LDL-C, and TC. Owing to the data availability, the
percentage of missing data at baseline is as follows: body mass
index (25.25%), diastolic blood pressure (23.54%), systolic
blood pressure (18.27%), HbA1c (28.09%), LDL-C (46.21%),
and TC (45.92%). We will use multiple imputation and
consequently carry out a sensitivity analysis with and without
imputation of missing data on all covariates. Our study will be
the first population-based cohort study that systematically
investigates the impacts of treatment adherence for patients with
both diabetes and hypertension on CVD morbidity and mortality,
and clinical treatment outcomes using a longitudinal and
large-scale primary care EMR data. Our findings will help to
identify challenges in treatment adherence for patients with
diabetes and hypertension in primary care settings. Through
this study, we hope to provide valuable evidence for policy and
practice to inform the design and implementation of primary
care health services to support adherence among patients living
with diabetes and hypertension.
Limitations
Several limitations should be noted in our study. First, this study
is a retrospective study. All data were recorded from routine
EMRs with possible errors and omissions. Thus, CVD may not
be captured in full. As recording the medical diagnosis of
diabetes, hypertension, and CVD is the responsibility of primary
care physicians, there may be delays in EMR input. Second,
treatment adherence is measured using a proxy, not a real
measure. Theoretically, patients with both diabetes and
hypertension are regarded as having a high risk of CVD events
and should take prescribed medications consistently. We assume
that prescription patterns correspond to medication-taking
behavior. Third, owing to data limitations, we estimate CVD
mortality using systolic blood pressure distributions and the
population attributable risks related to the systolic blood pressure
level. Fourth, aspirin is an over-the-counter medication that
patients can obtain from pharmacies without a prescription.
Thus, we may underestimate the adherence rates for aspirin.
Finally, we employed the Social Cognitive Theory to explore
the reciprocal relationship between that treatment adherence
and diabetes/hypertension management outcomes (such as
CVD), in the context of personal factors and environmental
determinants. However, there were many factors not recorded
in our database. For example, there were no variables such as
primary language, ethnicity, health literacy, employment status,
and marital status, which are factors contributing to patient
understanding of the treatment or related to their daily
management. There were no process variables recorded such
as patient’s level of involvement in the treatment
decision-making process, understanding of their disease, and
family and social support. In addition, there was a lack of
reporting on physician-specific variables, such as the level of
communication to patients on the benefits and adverse effects
of a prescription nor did we have variables related to the health
system such as access to primary care and primary care models
[15]. These limitations may lead to potential bias.
 
Acknowledgments
We would like to acknowledge the Strategy for Patient-Oriented Research network in Chronic Diseases, Diabetes Action Canada,
as well as Tao Chen and Conard Pow, who gave substantial technical and administrative support for data processing. Our data
source was Diabetes Action Canada’s National Diabetes Repository. The results or views expressed are those of the authors and
not necessarily of Diabetes Action Canada. The study received partial in-kind funding from Diabetes Action Canada (503854).
This study has not been published previously and is not under consideration for publication elsewhere. If accepted, this work will
not be published elsewhere without the written consent of the copyright holder.
Frank Sullivan’s main affiliation is School of Medicine, University of St Andrews, and also Department of Family and Community
Medicine and Dalla Lana School of Public Health, University of Toronto.
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.7http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Michelle Greiver’s main affiliation is North York General Hospital, and also Department of Family and Community Medicine,
University of Toronto.
Authors' Contributions
XW obtained funding and led the study. XW, and MS conceived and designed the study. XW and MS managed the literature
searches and formulated the research questions. MS, XW, and VH wrote the draft of the protocol. VH, RU, FS, FL, MG, and
XW reviewed the protocol. All authors contributed to and approved the current version of the protocol
Conflicts of Interest
None declared.
Multimedia Appendix 1
Study characteristics.
[DOCX File, 149KB - resprot_v8i5e13571_app1.pdf ]
Multimedia Appendix 2
Lag lead method.
[PDF File (Adobe PDF File), 361KB - resprot_v8i5e13571_app2.pdf ]
References
1. Statistics Canada. Table 13-10-0394-01 Leading causes of death, total population, by age group URL: https://www150.
statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401 [accessed 2019-04-30] [WebCite Cache ID 7817NCgwx]
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, American Heart Association Councils on Kidney
in Cardiovascular Disease‚ High Blood Pressure Research‚ Clinical Cardiology‚ Epidemiology and Prevention. Kidney
disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils
on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Hypertension 2003 Nov;42(5):1050-1065. [doi: 10.1161/01.HYP.0000102971.85504.7c] [Medline: 14604997]
3. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States,
1988-2012. J Am Med Assoc 2015 Sep 8;314(10):1021-1029. [doi: 10.1001/jama.2015.10029] [Medline: 26348752]
4. Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al. Association of history of gestational diabetes with
long-term cardiovascular disease risk in a large prospective cohort of US women. JAMA Intern Med 2017 Dec
01;177(12):1735-1742 [FREE Full text] [doi: 10.1001/jamainternmed.2017.2790] [Medline: 29049820]
5. Statistics Canada. Table13-10-0096-09 High blood pressure, by age group URL: https://www150.statcan.gc.ca/t1/tbl1/en/
tv.action?pid=1310009609 [accessed 2019-04-30] [WebCite Cache ID 7817adT4O]
6. Cloutier L, Lamarre-Cliche M. Hypertension in adults with type 2 diabetes: a review of blood pressure measurement
methods, targets and therapy. Can J Diabetes 2018 Apr;42(2):188-195. [doi: 10.1016/j.jcjd.2018.01.012] [Medline: 29602406]
7. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012
Apr;14(2):160-166 [FREE Full text] [doi: 10.1007/s11883-012-0227-2] [Medline: 22281657]
8. Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature
review. Patient Prefer Adherence 2017;11:1103-1117 [FREE Full text] [doi: 10.2147/PPA.S136639] [Medline: 28721024]
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections
for 2030. Diabetes Care 2004 May;27(5):1047-1053. [Medline: 15111519]
10. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic
patients: national health and nutrition examination surveys 1988-2010. Circulation 2013 Jul 02;128(1):29-41 [FREE Full
text] [doi: 10.1161/CIRCULATIONAHA.112.000500] [Medline: 23817481]
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4;353(5):487-497. [doi: 10.1056/NEJMra050100]
[Medline: 16079372]
12. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure URL: https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf
[accessed 2019-05-06] [WebCite Cache ID 78A27Tyut]
13. The sixth report of the Joint National Committee. The sixth report of the Joint National Committee on prevention, detection,
evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov 24;157(21):2413-2446. [Medline: 9385294]
14. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical
factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005 Jun;12(3):243-249 [FREE Full text] [Medline:
15942423]
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.8http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
15. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011 Apr;86(4):304-314 [FREE Full text]
[doi: 10.4065/mcp.2010.0575] [Medline: 21389250]
16. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence:
terminology and definitions. Value Health 2008;11(1):44-47 [FREE Full text] [doi: 10.1111/j.1524-4733.2007.00213.x]
[Medline: 18237359]
17. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015;2015:217047 [FREE Full text]
[doi: 10.1155/2015/217047] [Medline: 26539470]
18. Elwyn G, Edwards A, Britten N. What information do patients need about medicines? “Doing prescribing”: how doctors
can be more effective. Br Med J 2003 Oct 11;327(7419):864-867 [FREE Full text] [doi: 10.1136/bmj.327.7419.864]
[Medline: 14551110]
19. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific
review. J Am Med Assoc 2002 Dec 11;288(22):2868-2879. [Medline: 12472329]
20. Moon SJ, Lee W, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: a systematic
review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One 2017;12(11):e0187139 [FREE Full
text] [doi: 10.1371/journal.pone.0187139] [Medline: 29095870]
21. Hennein R, Hwang S, Au R, Levy D, Muntner P, Fox CS, et al. Barriers to medication adherence and links to cardiovascular
disease risk factor control: the Framingham Heart Study. Intern Med J 2018 Dec;48(4):414-421. [doi: 10.1111/imj.13687]
[Medline: 29193523]
22. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence.
Med Care 1986 Jan;24(1):67-74. [Medline: 3945130]
23. Barner JC. ISPOR Student Forum Presentation. Medication adherence: focus on secondary database analysis URL: https:/
/docplayer.net/41237212-Medication-adherence-focus-on-secondary [accessed 2019-04-29] [WebCite Cache ID 7817sIVcr]
24. van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose
combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat 2014;2014:967073 [FREE
Full text] [doi: 10.1155/2014/967073] [Medline: 25276422]
25. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a
proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7-8):1280-1288. [doi:
10.1345/aph.1H018] [Medline: 16868217]
26. Karlsson SA, Hero C, Svensson A, Franzén S, Miftaraj M, Gudbjörnsdottir S, et al. Association between refill adherence
to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes
mellitus: a nationwide cohort study. BMJ Open 2018 Dec 30;8(3):e020309 [FREE Full text] [doi:
10.1136/bmjopen-2017-020309] [Medline: 29602853]
27. Kim J, Kim E, Lee E. Evaluation of the chronic disease management program for appropriateness of medication adherence
and persistence in hypertension and type-2 diabetes patients in Korea. Medicine (Baltimore) 2017 Apr;96(14):e6577 [FREE
Full text] [doi: 10.1097/MD.0000000000006577] [Medline: 28383439]
28. Shin S, Song H, Oh S, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for
cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2013 Nov;36(11):1000-1005. [doi:
10.1038/hr.2013.85] [Medline: 23966057]
29. Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease
among older adults: a population-based cohort study. J Am Heart Assoc 2017 Jun 24;6(6) [FREE Full text] [doi:
10.1161/JAHA.117.006056] [Medline: 28647688]
30. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Better adherence to antihypertensive agents and risk
reduction of chronic heart failure. J Intern Med 2009 Aug;266(2):207-218. [Medline: 19623691]
31. Roy L, White-Guay B, Dorais M, Dragomir A, Lessard M, Perreault S. Adherence to antihypertensive agents improves
risk reduction of end-stage renal disease. Kidney Int 2013 Sep;84(3):570-577 [FREE Full text] [doi: 10.1038/ki.2013.103]
[Medline: 23698228]
32. Liu Q, Quan H, Chen G, Qian H, Khan N. Antihypertensive medication adherence and mortality according to ethnicity: a
cohort study. Can J Cardiol 2014 Aug;30(8):925-931. [doi: 10.1016/j.cjca.2014.04.017] [Medline: 25064583]
33. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence,
and clinical outcomes: a population-based retrospective cohort study. PLoS Med 2018 Jun;15(6):e1002584 [FREE Full
text] [doi: 10.1371/journal.pmed.1002584] [Medline: 29889841]
34. Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, et al. Impact of adherence to antihypertensive agents on clinical
outcomes and hospitalization costs. Med Care 2010 May;48(5):418-425. [doi: 10.1097/MLR.0b013e3181d567bd] [Medline:
20393367]
35. Wu P, Yang C, Yao Z, Lin W, Wu L, Chang C. Relationship of blood pressure control and hospitalization risk to medication
adherence among patients with hypertension in Taiwan. Am J Hypertens 2010 Feb;23(2):155-160. [doi: 10.1038/ajh.2009.210]
[Medline: 19927135]
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.9http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
36. Raebel MA, Dyer W, Nichols GA, Goodrich GK, Schmittdiel JA. Relationships between medication adherence and
cardiovascular disease risk factor control in elderly patients with diabetes. Pharmacotherapy 2017 Oct;37(10):1204-1214
[FREE Full text] [doi: 10.1002/phar.1994] [Medline: 28752555]
37. Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Effectiveness of digital medicines to improve clinical outcomes
in patients with uncontrolled hypertension and type 2 diabetes: prospective, open-label, cluster-randomized pilot clinical
trial. J Med Internet Res 2017 Jul 11;19(7):e246 [FREE Full text] [doi: 10.2196/jmir.7833] [Medline: 28698169]
38. Cohen HW, Shmukler C, Ullman R, Rivera CM, Walker EA. Measurements of medication adherence in diabetic patients
with poorly controlled HbA(1c). Diabet Med 2010 Feb;27(2):210-216 [FREE Full text] [doi:
10.1111/j.1464-5491.2009.02898.x] [Medline: 20546266]
39. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin
A1c in type 2 diabetes. Ann Pharmacother 2004 Sep;38(9):1357-1362. [doi: 10.1345/aph.1D612] [Medline: 15238621]
40. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure,
and low-density lipoprotein cholesterol: a randomized controlled trial. J Am Med Assoc 2006 Dec 06;296(21):2563-2571.
[doi: 10.1001/jama.296.21.joc60162] [Medline: 17101639]
41. Gentil L, Vasiliadis H, Préville M, Berbiche D. Adherence to Oral Antihyperglycemic Agents Among Older Adults With
Mental Disorders and Its Effect on Health Care Costs, Quebec, Canada, 2005-2008. Prev Chronic Dis 2015 Dec 31;12:E230
[FREE Full text] [doi: 10.5888/pcd12.150412] [Medline: 26719900]
42. Simard P, Presse N, Roy L, Dorais M, White-Guay B, Räkel A, et al. Persistence and adherence to oral antidiabetics: a
population-based cohort study. Acta Diabetol 2015 Jun;52(3):547-556. [doi: 10.1007/s00592-014-0692-x] [Medline:
25524433]
43. Guénette L, Breton M, Guillaumie L, Lauzier S, Grégoire J, Moisan J. Psychosocial factors associated with adherence to
non-insulin antidiabetes treatments. J Diabetes Complications 2016 Mar;30(2):335-342. [doi: 10.1016/j.jdiacomp.2015.10.016]
[Medline: 26615905]
44. Grégoire J, Sirois C, Blanc G, Poirier P, Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated
patients--a population-based study. Value Health 2010;13(6):820-828 [FREE Full text] [doi:
10.1111/j.1524-4733.2010.00761.x] [Medline: 21054658]
45. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K, Canadian Hypertension Education Program Outcomes Research
Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario. Am
J Med 2010 Feb;123(2):173-181. [doi: 10.1016/j.amjmed.2009.08.008] [Medline: 20103027]
46. Gee ME, Campbell NR, Gwadry-Sridhar F, Nolan RP, Kaczorowski J, Bienek A, Outcomes Research Task Force of the
Canadian Hypertension Education Program. Antihypertensive medication use, adherence, stops, and starts in Canadians
with hypertension. Can J Cardiol 2012 May;28(3):383-389. [doi: 10.1016/j.cjca.2012.01.014] [Medline: 22522073]
47. Natarajan N, Putnam W, Van Aarsen K, Beverley Lawson K, Burge F. Adherence to antihypertensive medications among
family practice patients with diabetes mellitus and hypertension. Can Fam Physician 2013 Feb;59(2):e93-e100 [FREE Full
text] [Medline: 23418264]
48. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for
health care, research, and medical education: a cross-sectional study. Lancet 2012 Jul 7;380(9836):37-43 [FREE Full text]
[doi: 10.1016/S0140-6736(12)60240-2] [Medline: 22579043]
49. Aagaard EM, Gonzales R, Camargo CA, Auten R, Levin SK, Maselli J, et al. Physician champions are key to improving
antibiotic prescribing quality. Jt Comm J Qual Patient Saf 2010 Mar;36(3):109-116. [Medline: 20235412]
50. Wei X, Walley JD, Zhang Z, Zou G, Gong W, Deng S, et al. Implementation of a comprehensive intervention for patients
at high risk of cardiovascular disease in rural China: a pragmatic cluster randomized controlled trial. PLoS One
2017;12(8):e0183169 [FREE Full text] [doi: 10.1371/journal.pone.0183169] [Medline: 28813512]
51. Zullig LL, Blalock DV, Dougherty S, Henderson R, Ha CC, Oakes MM, et al. The new landscape of medication adherence
improvement: where population health science meets precision medicine. Patient Prefer Adherence 2018;12:1225-1230
[FREE Full text] [doi: 10.2147/PPA.S165404] [Medline: 30034226]
52. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2003 Dec;2(4):323.
[Medline: 14667488]
53. Ong SE, Koh JJ, Toh SE, Chia KS, Balabanova D, McKee M, et al. Assessing the influence of health systems on type 2
diabetes mellitus awareness, treatment, adherence, and control: a systematic review. PLoS One 2018;13(3):e0195086 [FREE
Full text] [doi: 10.1371/journal.pone.0195086] [Medline: 29596495]
54. Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. J Am
Med Assoc 2013 Dec 25;310(24):2611-2612. [doi: 10.1001/jama.2013.282818] [Medline: 24264605]
55. Bandura A. Health promotion by social cognitive means. Health Educ Behav 2004 Apr;31(2):143-164. [doi:
10.1177/1090198104263660] [Medline: 15090118]
56. Bandura A. Exercise of human agency through collective efficacy. Curr Dir Psychol Sci 2000;9(3):75-78. [doi:
10.1111/1467-8721.00064]
57. Bandura A. Social cognitive theory: an agentic perspective. Annu Rev Psychol 2001;52:1-26. [doi:
10.1146/annurev.psych.52.1.1] [Medline: 11148297]
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.10http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
58. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q 1984;11(1):1-47. [Medline: 6392204]
59. Ajzen I, Madden TJ. Prediction of goal-directed behavior: attitudes, intentions, and perceived behavioral control. J Exp
Soc Psychol 1986 1986 Sep;22(5):453-474. [doi: 10.1016/0022-1031(86)90045-4]
60. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process 1991 Dec;50(2):179-211. [doi:
10.1016/0749-5978(91)90020-T]
61. Stokols D. Translating social ecological theory into guidelines for community health promotion. Am J Health Promot
1996;10(4):282-298. [Medline: 10159709]
62. Guirguis-Blake J, Keppel GA, Force RW, Cauffield J, Monger RM, Baldwin LM. Variation in refill protocols and procedures
in a family medicine residency network. Fam Med 2012 Sep;44(8):564-568 [FREE Full text] [Medline: 22930121]
63. Sturman M, McCabe D. Choosing whether to lead, lag, or match the market. Journal of Human Resources in Hospitality
& Tourism 2006;7(1):85-97. [doi: 10.1300/J171v07n01_05]
64. Rigobon AV, Kalia S, Nichols J, Aliarzadeh B, Greiver M, Moineddin R, et al. Impact of the Diabetes Canada Guideline
Dissemination Strategy on the prescription of vascular protective medications: a retrospective cohort study, 2010-2015.
Diabetes Care 2019 Jan;42(1):148-156. [doi: 10.2337/dc18-0935] [Medline: 30389671]
65. Chen H, Burnett RT, Kwong JC, Villeneuve PJ, Goldberg MS, Brook RD, et al. Spatial association between ambient fine
particulate matter and incident hypertension. Circulation 2014 Feb 04;129(5):562-569. [doi:
10.1161/CIRCULATIONAHA.113.003532] [Medline: 24190962]
66. Tu JV, Chu A, Rezai MR, Guo H, Maclagan LC, Austin PC, et al. The incidence of major cardiovascular events in immigrants
to Ontario, Canada: the CANHEART immigrant study. Circulation 2015 Dec 20;132(16):1549–1559 [FREE Full text] [doi:
10.1161/CIRCULATIONAHA.115.015345] [Medline: 26324719]
67. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2014 Hypertension
Guidelines with cardiovascular events and deaths in US adults. JAMA Cardiol 2018 Jul 01;3(7):572. [doi:
10.1001/jamacardio.2018.1240] [Medline: 29800138]
68. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular
disease and mortality. JAMA Cardiol 2017 Jul 01;2(7):775. [doi: 10.1001/jamacardio.2017.1421]
69. Canadian Institute for Health Information. 2008. Reducing gaps in health: a focus on socio-economic status in urban Canada
URL: https://secure.cihi.ca/free_products/Reducing_Gaps_in_Health_Report_EN_081009.pdf [accessed 2019-05-06]
[WebCite Cache ID 78A3gj0rb]
70. Pampalon R, Hamel D, Gamache P, Philibert MD, Raymond G, Simpson A. An area-based material and social deprivation
index for public health in Québec and Canada. Can J Public Health 2012 Apr 30;103(8 Suppl 2):S17-S22 [FREE Full text]
[Medline: 23618066]
71. Wei X, Barnsley J, Zakus D, Cockerill R, Glazier R, Sun X, et al. Evaluation of a diabetes management program in China
demonstrated association of improved continuity of care with clinical outcomes. J Clin Epidemiol 2008 Sep;61(9):932-939.
[doi: 10.1016/j.jclinepi.2007.12.013] [Medline: 18619807]
72. Birtwhistle R, Keshavjee K, Lambert-Lanning A, Godwin M, Greiver M, Manca D, et al. Building a pan-Canadian primary
care sentinel surveillance network: initial development and moving forward. J Am Board Fam Med 2009;22(4):412-422
[FREE Full text] [doi: 10.3122/jabfm.2009.04.090081] [Medline: 19587256]
73. Chao J, Nau DP, Aikens JE, Taylor SD. The mediating role of health beliefs in the relationship between depressive symptoms
and medication adherence in persons with diabetes. Res Social Adm Pharm 2005 Dec;1(4):508-525. [doi:
10.1016/j.sapharm.2005.09.002] [Medline: 17138493]
74. Kilbourne A, Reynolds IC, Good C, Sereika S, Justice A, Fine MJ. How does depression influence diabetes medication
adherence in older patients? Am J Geriatr Psychiatry 2005 Mar;13(3):202-210. [doi: 10.1176/appi.ajgp.13.3.202] [Medline:
15728751]
75. Ekström N, Svensson A, Miftaraj M, Franzén S, Zethelius B, Eliasson B, et al. Cardiovascular safety of glucose-lowering
agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Diabetes Obes Metab 2016 Jan;18(10):990-998. [doi: 10.1111/dom.12704] [Medline: 27282621]
Abbreviations
CPCSSN: Canadian Primary Care Sentinel Surveillance Network
CVD: cardiovascular disease
EMR: electronic medical record
HbA1c: glycated hemoglobin
LDL-C: low-density lipoprotein cholesterol
PAR: population attributable risk
SES: socioeconomic status
TC: total cholesterol
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.11http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Edited by G Eysenbach; submitted 31.01.19; peer-reviewed by P Fresco, E Meinert; comments to author 13.03.19; revised version
received 31.03.19; accepted 02.04.19; published 20.05.19
Please cite as:
Su M, Haldane V, Upshur R, Sullivan F, Légaré F, Greiver M, Wei X
The Impact of Treatment Adherence for Patients With Diabetes and Hypertension on Cardiovascular Disease Risk: Protocol for a
Retrospective Cohort Study, 2008-2018
JMIR Res Protoc 2019;8(5):e13571
URL: http://www.researchprotocols.org/2019/5/e13571/ 
doi:10.2196/13571
PMID:
©Min Su, Victoria Haldane, Ross Upshur, Frank Sullivan, France Légaré, Michelle Greiver, Xiaolin Wei. Originally published
in JMIR Research Protocols (http://www.researchprotocols.org), 20.05.2019. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is
properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org,
as well as this copyright and license information must be included.
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e13571 | p.12http://www.researchprotocols.org/2019/5/e13571/
(page number not for citation purposes)
Su et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
